ROR2

Across TCGA pan-cancer cohorts, ROR2 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated ROR2 data layer compared with 24 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher ROR2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ROR2 expression acts as an unfavorable survival marker.

ESCA, LIHC, and LUSC are the cancer types where ROR2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.117	0.687	<.001	33	view →
LIHC	OS	Median	All	0.250	0.794	<.001	26	view →
LUSC	OS	Median	III,IV	0.112	0.664	.003	12	view →
CESC	DFS	Median	IV	0.053	0.529	<.001	6	view →
LGG	OS	Median	All	0.610	0.889	.005	6	view →
ACC	OS	Median	All	0.118	0.624	.038	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	OS	Median	IV	0.415	0.861	.014	6	view →
BRCA	OS	Median	All	0.748	0.925	.026	4	view →
SARC	OS	Median	All	0.241	0.766	.022	3	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

ROR2–ESCA (OS)

Open the ESCA breakdown →